GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid prescription medicines, reported a 51% spike in Q3 revenue to $137.1 million, surpassing the Wall Street consensus. Net earnings narrowed to 0.03 per share, stronger than the target that analysts had projected.
GWPH shares gained 19% during market hours. The stock has increased 4% since the beginning of this year.
Epidiolex accounted for a lion’s share of the total revenues, contributing $132.6 million in Q3.
CEO Justin Gover said, “We have also now commenced the pivotal Phase 3 program for nabiximols in the treatment of multiple sclerosis spasticity, which provides multiple opportunities for an NDA submission, including as early as next year. Beyond nabiximols, we are advancing several clinical-stage pipeline candidates, including the recent start of a Phase 2 trial in schizophrenia.”
____
Most Popular
Mattel (MAT): A look at the toymaker’s expectations for the year
Shares of Mattel, Inc. (NASDAQ: MAT) were up slightly on Thursday. The stock has gained 20% year-to-date and 19% over the past three months. There is a level of optimism
Earnings Preview: Paychex likely to report higher Q1 revenue and profit
Paychex Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is all set to publish operating results for the first three months of fiscal 2024. The company has
DRI Earnings: Key quarterly highlights from Darden Restaurants’ Q1 2024 financial results
Darden Restaurants, Inc. (NYSE: DRI) reported first quarter 2024 earnings results today. Total sales increased 11.6% to $2.73 billion compared to the same period last year. Blended same-restaurant sales were
